Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- ISCA +9.3%, ZUMZ +9%, (Zumiez raises Q3 comps/sales guidance and reports Sept comps +9.3% vs +6.3% year ago and +7.4% last month)
- STZ +4.4%, STFC +3.9%, (reported est catastrophe results for Q3), TMQ+3.4%, RECN +1.1%
Other news:
- MOBL +9.3% (after Altai Capital Management disclosed 7.63% stake; expects to continue to engage in, discussions with members of management and the board)
- ACAD +6% ( initiates Phase III study to evaluate pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis; FDA grants breakthrough therapy designation to pimavanserin for dementia-related psychosis)
- MDCO +5.8% (presents new data from its TANGO II study of VABOMERE )
- SEAS +5.3% (continued strength on reports of possible sale after being approached by Merlin Entertainment )
- CDNA +5.2% (prices underwritten public offering of 4,341,600 shares of its common stock at $4.00/share)
- MTW +4.8% (following CNBC Fast Money mention)
- PPBI +4.7% (will replace Parkway in the S&P SmallCap 600)
- CATB +4.3% (modestly pulling back after 40%+ move higher over the past three days)
- FMSA +4.2% (reinitiated after the close at Keybanc)
- NCLH +3.6% (will replace Level 3 Communications in the S&P 500)
- NBIX +3.1% (FDA has approved an 80 mg INGREZZA )
- CMCM +2.2% (after closing near lows)
- LC +1.4% (Sohn conference presenter Seth Wunder of Black-and-White Capital comments - thinks balance sheet risk is 'misunderstood')
- BRG +1.3% (terminates two At Market Issuance Sales Agreement)
Analyst comments:
- BIIB +2.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- RGC +1% (upgraded to Equal-Weight at Morgan Stanley)